Ignite Creation Date:
2024-05-05 @ 11:26 PM
Last Modification Date:
2024-10-26 @ 10:34 AM
Study NCT ID:
NCT01338740
Status:
COMPLETED
Last Update Posted:
2023-01-05
First Post:
2011-04-18
Brief Title:
Switching From Adalimumab to Infliximab
Sponsor:
Organization:
University Hospital Ghent
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
SAMPLES_WITHOUT_DNA
Bio Spec Description:
At regular intervals the results of interim blood tests will be documented 3x
After 10 26 and 52 weeks additional serum samples will be taken for determination of antibodies against Adalimumab and Infliximab The serum levels of Adalimumab week 0 and Infliximab week 10 26 and 52 will be determined
Enrollment Count:
21
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Case-Only |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 14149 |
Who Masked List: